Bristol Myers Squibbvs.Johnson & Johnson
BMY vs JNJ · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 5.3× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (19.6 vs 29.5); year to date, Johnson & Johnson leads (+24.2% vs +6.7%).
Side by side
| BMY | JNJ | |
|---|---|---|
| Market cap | $117B | $620B |
| Price | $57.58 | $256.98 |
| Today | −0.6% | −0.8% |
| Return YTD | +6.7% | +24.2% |
| Return 1Y | +18.7% | +63.0% |
| P/E | 19.6 | 29.5 |
| P/S | 2.4 | 6.4 |
| P/B | 5.8 | 7.6 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Bristol Myers SquibbBMY
American pharmaceutical group with strengths in oncology (Opdivo) and immunology, plus a neuroscience pipeline.
Full BMY profile →Johnson & JohnsonJNJ
American healthcare group with a large pharmaceutical division (Innovative Medicine) and medtech division (MedTech).
Full JNJ profile →More comparisons in Big pharma
See where BMY and JNJ sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →